BioTuesdays

Category - Feature

Feature

In conversation with Rudy Mazzocchi

By Len Zehr As president and CEO of closely-held ELENZA, Rudy Mazzocchi knows a thing or two about taking startups across the finish line. Among other things, he was the founder of eV3, which is now part of Covidien...

August 27, 2013
Feature

Galectin targets silent epidemic in liver fibrosis

By Len Zehr Fatty liver disease, or the accumulation of fat in liver cells, is a “silent epidemic,” says Dr. Peter Traber, president, CEO and chief medical officer of Galectin Therapeutics (NASDAQ:GALT). In an interview...

August 20, 2013
Feature

RedHill readying Phase 3 trials in Crohn’s

By Len Zehr With a PDUFA target date of Feb. 3, 2014 for its migraine drug, RHB-103, and NDA filing planned for the first quarter of 2014 for the anti-emetic drug, RHB-102, RedHill Biopharma (NASDAQ,:RDHL; TASE:RDHL) is...

August 13, 2013
Feature

Elite eyes home run in abuse-resistant technology

By Len Zehr After reinventing itself in 2011, Elite Pharmaceuticals (OTCBB:ELTP) has bounced back with a line of generic drugs and is banking on the development of abuse-resistant opioids and once-daily opioid products...

August 6, 2013
Feature

In conversation with Todd Wyche

By Len Zehr As CEO and a co-founder of Brinson Patrick Securities, Todd Wyche has championed the use and growth of at-the-market offerings (ATMs) for the past 17 years for REITs, energy companies and most recently...

July 2, 2013
Feature

Avivagen shifts to commercial mindset from R&D

By Len Zehr Cameron Groome, who moved into the executive suite at Avivagen (TSX-V:VIV) in March, has transformed the focus of the animal wellness company to a business and product development engine and away from an...

June 18, 2013
Feature

Oramed readies oral insulin study in U.S.

By Len Zehr Oramed Pharmaceuticals (NASDAQ:ORMP) is awaiting a decision from the FDA, possibly later this week, to conduct a sub-study of the safety of its oral insulin candidate, ORMD-0801, before proceeding to a...

May 7, 2013
Feature

Vaxil trial validates vaccine technology

By Len Zehr Results of a recent clinical trial of Vaxil Bio’s (TASE:VAXL) ImMucin cancer vaccine in patients with multiple myeloma has validated the company’s VaxHit technology by demonstrating safety and a strong...

April 23, 2013